DBV Technologies SA
PAR:DBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DBV Technologies SA
Net Change in Cash
DBV Technologies SA
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DBV Technologies SA
PAR:DBV
|
Net Change in Cash
$161.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
121%
|
CAGR 10-Years
-3%
|
|
|
Valneva SE
PAR:VLA
|
Net Change in Cash
-€58.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Change in Cash
€19.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Net Change in Cash
€2.7m
|
CAGR 3-Years
147%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Net Change in Cash
€225m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Net Change in Cash
-€59.7m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-38%
|
|
DBV Technologies SA
Glance View
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
See Also
What is DBV Technologies SA's Net Change in Cash?
Net Change in Cash
161.7m
USD
Based on the financial report for Dec 31, 2025, DBV Technologies SA's Net Change in Cash amounts to 161.7m USD.
What is DBV Technologies SA's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
-3%
The average annual Net Change in Cash growth rates for DBV Technologies SA have been 7% over the past three years , 121% over the past five years , and -3% over the past ten years .
